Journal of Bone Research
Open Access

Abstract

Not all Bone Metastases are the Same: Treatment Resistance in Renal Cell Carcinoma Revisited

Mikako Suitz

Renal Cell Carcinoma (RCC) is the most frequent malignancy of the kidney, accounting for 80–90% of all renal neoplasms and having a five-year overall survival rate of around 74%. Bone is the second most common location of metastasis. RCC Bone Metastases (RCCBM) treatment failure is becoming more common as patients live longer because to new RCC targeted medicines and immunotherapy. In RCC, the occurrence of bone metastases indicates a more aggressive illness with a worse prognosis. Identification of essential pathways underlying RCCBM-induced anabolic impairment could provide needed insight on how to enhance treatment results for patients with RCCBM, with the goals of limiting progression and enhancing survival.

Published Date: 2021-12-31; Received Date: 2021-12-15